On a consolidated basis, profit before tax rose 1.46% to Rs 599 crore in Q3 December 2021 over Q3 December 2020.
Earnings before Interest, Depreciation and Tax (EBIDTA) stood at Rs 753 crore, down 1.83% YoY and down 12.54% QoQ.
India formulations business posted revenues of Rs 1079 crore during the quarter. The branded formulations business posted a robust double-digit growth of 17% on a y-o-y basis.
US formulations business registered revenues of Rs 1504 crore during the quarter. The company filed 12 additional ANDAs with the USFDA during the quarter and received 9 new product approvals (including 5 tentative approvals) from the USFDA. The company launched 3 new products in the US market including Nelarabine injection which was granted 180 days exclusivity and was a day 1 launch. It is a chemotherapy drug used to treat certain types of leukemia and lymphoma.
Cadila Healthcare is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
Powered by Capital Market – Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.